Immune Checkpoint Inhibitor Outcomes for Patients With Non–Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications Median time to relapse was 7.4 ...
Approximately 20% of patients with clinical stage I seminoma relapse. Tumor size and rete testis invasion have been identified as risk factors for relapse. However, the level of evidence supporting ...
Investigators sought to determine whether adjuvant pembrolizumab is associated with the risk of developing subsequent cutaneous malignant neoplasms in patients with high-risk stage II melanoma.
Nearly everyone with multiple myeloma relapses. That doesn’t make it easy. A cancer diagnosis is traumatic, especially when the cancer is treatable, but not curable. In multiple myeloma, the disease ...
More than half of patients with BRAF-mutated advanced melanoma taking Tafinlar+ Mekinist were alive and free of a relapse at 5- years 1 Study conclusions are drawn from the largest dataset and longest ...
A second clinical trial testing fenebrutinib for MS has met its main goal, once again beating approved Aubagio in reducing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results